The shares of healthcare company AstraZeneca (AZN.UK) are losing more than 4.5 per cent and have suffered their biggest daily fall since 2021 as details surrounding the company's lung cancer treatment are lacking.
The drug helped patients with the most common form of lung cancer live longer without worsening their overall health compared to standard chemotherapy, the company announced today. However, investors had expected a clearer statement on the trial's success in terms of progression-free survival, as well as by how much overall life expectancy is extended.
Start investing today or test a free demo
Open account Try demo Download mobile app Download mobile appAs Jefferies analysts report, it was the lack of detailed data that failed to meet market expectations. Furthermore, several people on the treatment have died, raising concerns about the safety of the product. At the moment, detailed data on this topic is unknown.
Dato-DXd, the company's proprietary formulation, is primarily designed to attack cancer cells directly and not in general as is the case with general chemotherapy. Market consesnus assume that a successful launch of the solution could generate an additional USD 19 billion in revenue for the company. Despite today's declines, bank analysts are reiterating their 'buy' ratings on the company's shares.
Astra Zenca (AZN.UK) is trading below the lower limit of the uptrend today. Source: xStation 5
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
